EA201791761A1 - Композиция на основе олеаноил-пептида и повышение содержания коллагена - Google Patents

Композиция на основе олеаноил-пептида и повышение содержания коллагена

Info

Publication number
EA201791761A1
EA201791761A1 EA201791761A EA201791761A EA201791761A1 EA 201791761 A1 EA201791761 A1 EA 201791761A1 EA 201791761 A EA201791761 A EA 201791761A EA 201791761 A EA201791761 A EA 201791761A EA 201791761 A1 EA201791761 A1 EA 201791761A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oleanoil
increase
based composition
peptide based
collagen content
Prior art date
Application number
EA201791761A
Other languages
English (en)
Other versions
EA035128B9 (ru
EA035128B1 (ru
Inventor
Мухаммед Маджид
Кальянам Нагабхушанам
Original Assignee
Мухаммед Маджид
Кальянам Нагабхушанам
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мухаммед Маджид, Кальянам Нагабхушанам filed Critical Мухаммед Маджид
Priority claimed from PCT/US2015/067277 external-priority patent/WO2016126343A1/en
Publication of EA201791761A1 publication Critical patent/EA201791761A1/ru
Publication of EA035128B1 publication Critical patent/EA035128B1/ru
Publication of EA035128B9 publication Critical patent/EA035128B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Emergency Medicine (AREA)

Abstract

Описан способ восстановления и повышения упругости кожи, включающий стадию приведения пентапептидного конъюгата олеаноловой кислоты в контакт с клетками кожи, так что реализуется эффект повышенного уровня клеточной коммуникации на молекулярном уровне с осуществлением экспрессии генов и белков в клетках кожи, что делает возможным восстановление и повышение упругости. Изобретение демонстрирует эффект пентапептидного конъюгата олеаноловой кислоты в повышении экспрессии трансформирующего фактора роста-β и фактора роста фибробластов в коже.
EA201791761A 2010-12-28 2015-12-22 Применение композиции на основе олеаноил-пептида в недостаточно увлажненной коже человека EA035128B9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/979,667 US8987212B2 (en) 2007-08-07 2010-12-28 Oleanoyl peptide composition and method of treating skin aging
US14/614,538 US20150148297A1 (en) 2007-08-07 2015-02-05 Oleanoyl peptide composition and collagen enhancement
PCT/US2015/067277 WO2016126343A1 (en) 2015-02-05 2015-12-22 Oleanoyl peptide composition and collagen enhancement

Publications (3)

Publication Number Publication Date
EA201791761A1 true EA201791761A1 (ru) 2017-11-30
EA035128B1 EA035128B1 (ru) 2020-04-30
EA035128B9 EA035128B9 (ru) 2020-08-07

Family

ID=45464381

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791761A EA035128B9 (ru) 2010-12-28 2015-12-22 Применение композиции на основе олеаноил-пептида в недостаточно увлажненной коже человека

Country Status (10)

Country Link
US (3) US8987212B2 (ru)
EP (1) EP2510919A3 (ru)
JP (3) JP6176893B2 (ru)
KR (1) KR20170101946A (ru)
AU (2) AU2011265587B2 (ru)
BR (1) BRPI1105822A2 (ru)
CA (1) CA2975170C (ru)
EA (1) EA035128B9 (ru)
MY (1) MY188723A (ru)
WO (1) WO2012091743A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987212B2 (en) * 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
MX2017008454A (es) 2014-12-23 2017-10-31 Avon Prod Inc Peptidos y su uso en el tratamiento de la piel.
EP3253400B1 (en) * 2015-02-05 2023-01-18 Muhammed Majeed Oleanoyl peptide composition
US9597274B2 (en) * 2015-06-17 2017-03-21 Avon Products, Inc. Peptides and their use in the treatment of skin
US10493020B2 (en) 2016-04-14 2019-12-03 The Procter & Gamble Company Method of improving the appearance of periorbital dyschromia
KR102007078B1 (ko) 2017-03-24 2019-08-05 (주)셀아이콘랩 콜라겐 생성을 촉진시키는 신규한 헵타펩타이드 단량체 및 이량체를 포함하는 피부 노화 방지를 위한 화장품 조성물
EP3681508A4 (en) 2017-09-14 2021-05-19 Phoenix Biotechnology, Inc. METHOD AND COMPOSITION FOR THE TREATMENT OF VIRAL INFECTION
JP7370966B2 (ja) 2017-09-14 2023-10-30 フェニックス・バイオテクノロジー・インコーポレイテッド 神経学的状態を治療するための方法および改善された神経保護組成物
AU2018335280B2 (en) * 2017-09-21 2021-10-28 Sami Labs Limited Process for preparing tripeptide containing oleanolic acid and its therapeutic applications thereof
AU2019249392B2 (en) * 2018-04-03 2022-10-20 Sami Labs Limited Skin care compositions and their applications
CN110143994B (zh) * 2019-03-22 2020-08-04 中国医学科学院药用植物研究所 辽东楤木单体皂苷衍生物及其制备方法和用途
CN110117307B (zh) * 2019-03-22 2020-08-04 中国医学科学院药用植物研究所 楤木皂苷衍生物及其制备方法和用途
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
SG11202105728YA (en) 2020-03-31 2021-11-29 Phoenix Biotechnology Inc Method and compositions for treating coronavirus infection
CZ308812B6 (cs) * 2020-04-09 2021-06-02 Contipro A.S. Pentapeptid odvozený od kaseinu a kompozice, která jej zahrnuje a jejich topické použit

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055298A (en) 1987-12-01 1991-10-08 Chemisches Laboratorium Dr. Kurt Richter Gmbh Cosmetic composition comprising an extracellular connective tissue matrix
US5198465A (en) 1991-06-19 1993-03-30 Dioguardi Francesco S Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
IL131543A (en) 1997-02-25 2005-08-31 Univ Michigan Cosmetic methods and compositions for preventing and treating chronological aging in human skin
US6809075B1 (en) 2000-05-30 2004-10-26 Connective Tissue Imagineering Llc Elastin peptide analogs and uses of same incombination with skin enhancing agents
FR2777183B1 (fr) * 1998-04-10 2001-03-02 Oreal Utilisation d'au moins un hydroxystilbene dans une composition destinee a favoriser la desquamation de la peau et composition le comprenant
FR2783169B1 (fr) * 1998-09-15 2001-11-02 Sederma Sa Utilisation cosmetique ou dermopharmaceutique de peptides pour la cicatrisation et pour l'amelioration de l'aspect cutane lors du vieillissement naturel ou accelere (heliodermie, pollution)
US6777389B1 (en) 1998-11-19 2004-08-17 Connective Tissue Imagineering Llc Cosmetic or dermatological use of 7-hydroxylated steroids in combination with elastin derived peptides
US6492326B1 (en) 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
BR0012033A (pt) * 1999-06-30 2002-03-19 Unilever Nv Composição cosmética para cuidado da pele, e, processos cosméticos para tratamento da pele envelhecida, fotoenvelhecida, seca, com linhas ou enrugada, para melhorar a função de barreira da pele, para melhorar a diferenciação dos ceratinócitos, para melhorar a produção de lipìdios pelos ceratinócitos, para melhorar a captação de glicose pelos ceratinócitos, e para melhorar a captação de ascorbato pelos ceratinócitos
US6794362B1 (en) 2000-05-30 2004-09-21 Connective Tissue Imagineering Llc Asparagine containing elastin peptide analogs
FR2813018B1 (fr) * 2000-08-21 2004-02-06 Boots Co Plc Compositions cosmetiques renfermant au moins un compose stimulant la neosynthese des laminines, et/ou de l'integrine alpha-2 beta-1 et/ou du collagene iv de la jonction dermo- epidermique
DE10121069A1 (de) * 2001-04-26 2002-10-31 Beiersdorf Ag Verwendung von Tetrahydrocurcuminoiden oder deren Derivaten als Wirkstoffe zur Herstellung von kosmetischen und dermatologischen Zubereitungen zum Schutz und zur Behandlung der trockenen bzw. alterstrockenen Haut
FR2826266B1 (fr) 2001-06-26 2005-02-25 Oreal Composition cosmetique ou dermatologique comprenant une association entre un compose de la famille des n-acylaminoamides et au moins un inhibiteur de metalloproteinases matricielles
US6906036B2 (en) 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US20030124205A1 (en) * 2001-12-28 2003-07-03 Avon Products, Inc. Topical cosmetic composition having a natural plant active ingredient and method of using same
KR100753472B1 (ko) * 2002-03-15 2007-08-31 주식회사 엘지생활건강 사람 콜라겐 ⅰ형의 ｃ-말단에서 유래된 펩타이드에ｔａｔ 펩타이드가 결합된 융합 펩타이드, 이의 제조방법,및 이를 포함하는 피부주름개선 화장료 조성물
US8691247B2 (en) * 2006-12-26 2014-04-08 Ad Lunam Labs Inc. Skin rejuvenation cream
US20090169651A1 (en) * 2007-06-28 2009-07-02 Muhammed Majeed Anti-skin damage compositions with complimentary dual mode of action
US8383594B2 (en) * 2007-08-07 2013-02-26 Sami Labs Limited Peptides modified with triterpenoids and small organic molecules: synthesis and use in cosmeceuticals
US8987212B2 (en) * 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
WO2010093848A1 (en) * 2009-02-13 2010-08-19 Invitrx, Inc. Skin cream

Also Published As

Publication number Publication date
US20150148297A1 (en) 2015-05-28
US20160113853A1 (en) 2016-04-28
CA2975170C (en) 2020-04-14
US10071043B2 (en) 2018-09-11
JP2018505890A (ja) 2018-03-01
AU2011265587B2 (en) 2017-01-05
BRPI1105822A2 (pt) 2018-11-21
AU2015381703B2 (en) 2020-02-20
MY188723A (en) 2021-12-25
JP2012140428A (ja) 2012-07-26
US20110091398A1 (en) 2011-04-21
KR20170101946A (ko) 2017-09-06
EP2510919A2 (en) 2012-10-17
EA035128B9 (ru) 2020-08-07
US8987212B2 (en) 2015-03-24
WO2012091743A1 (en) 2012-07-05
AU2015381703A1 (en) 2017-07-27
JP6176893B2 (ja) 2017-08-09
CA2975170A1 (en) 2016-08-11
AU2011265587A1 (en) 2012-07-12
EA035128B1 (ru) 2020-04-30
EP2510919A3 (en) 2014-08-13
JP2017206503A (ja) 2017-11-24

Similar Documents

Publication Publication Date Title
EA201791761A1 (ru) Композиция на основе олеаноил-пептида и повышение содержания коллагена
EA201300239A1 (ru) Антитела к fap и способы их применения
NZ592726A (en) Amnion derived adherent cells
RU2534564C3 (ru) Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
MX2014011459A (es) Proteinas nutritivas cargadas y metodos.
EA201400993A1 (ru) Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения
EA201390739A1 (ru) Способ лечения fgf21-ассоциированных расстройств
IN2012DN00377A (ru)
EA201171494A1 (ru) Миметики белка smac
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
MY160552A (en) Low protein infant formula with increased essential amino acids
WO2012071527A3 (en) Protein delivery from stem cell microcarriers
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
IN2015DN00976A (ru)
PA8813901A1 (es) Paramixovirus oncolíticos atenuados que codifican citoquinas de aves
EA201591593A1 (ru) Искусственные факторы транскрипции, сконструированные для предотвращения захвата эндосомами
MX2014011614A (es) Fragmentos y proteinas nutritivas con fenilalanina baja o nula y metodos.
EA201490945A1 (ru) Набор, содержащий заменитель сыворотки и лабильные факторы
PE20121533A1 (es) Metodo para producir l-aminoacido
MX354156B (es) Dipeptido que comprende un aminoacido no proteogenico.
EA201490032A1 (ru) Лиофилизированные препараты fgf-18
MX2011011351A (es) Agentes de imagenologia molecular etiquetados, metodos para hacerlos y metodos de uso.
CO6592086A2 (es) Metodo para producir proteinas de interferon recombiantes solubles sin desnaturalizacion

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM